Community hub
0 subscribers8 pages, 0 posts
Recent from talks
All channels
Be the first to start a discussion here.
Be the first to start a discussion here.
Be the first to start a discussion here.
Be the first to start a discussion here.
Contribute something
Welcome to the community hub built to collect knowledge and have discussions related to Anagliptin.
Nothing was collected or created yet.
Anagliptin
View on Wikipediafrom Wikipedia
 | |
| Clinical data | |
|---|---|
| Trade names | Suiny |
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C19H25N7O2 |
| Molar mass | 383.456 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Anagliptin (INN; trade name Suiny) is a pharmaceutical drug for the treatment of type 2 diabetes mellitus. It is approved for use in Japan.[1] It belongs to the class of anti-diabetic drugs known as dipeptidyl peptidase-4 inhibitors or "gliptins".[2]
Research
[edit]A systematic review and meta-analysis of anagliptin, published in 2024, found that it is effective in lowering blood glucose in people with type 2 diabetes and that it may lower cholesterol.[3]
References
[edit]- ^ Graul AI, Lupone B, Cruces E, Stringer M (January 2013). "2012 in review - part I: the year's new drugs & biologics" (PDF). Drugs of Today. 49 (1): 33–68. doi:10.1358/dot.2013.49.1.1933991. PMID 23362494. Archived from the original (PDF) on 2013-11-03.
- ^ Kato N, Oka M, Murase T, Yoshida M, Sakairi M, Yamashita S, et al. (December 2011). "Discovery and pharmacological characterization of N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor". Bioorganic & Medicinal Chemistry. 19 (23): 7221–7. doi:10.1016/j.bmc.2011.09.043. PMID 22019046.
- ^ Kamrul-Hasan AB, Dutta D, Nagendra L, Sharma M, Patra S, Bhattacharya S (July 2024). "Role of anagliptin, a dipeptidyl peptidase-4 inhibitor, in managing type 2 diabetes: A systematic review and meta-analysis". Medicine. 103 (28) e38870. doi:10.1097/MD.0000000000038870. PMC 11245198. PMID 38996148.
 | This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |